Myriad’s myRisk® Hereditary Cancer test is the market leading test for patients trying to understand their hereditary cancer risk.
The American Society of Breast Surgeons’ new guidelines recommend genetic testing for all people with breast cancer.1
myRisk® gives you the information needed to make a surgical decision with your patient based on their personal risk of developing cancer.
Myriad MyRisk Hereditary Cancer
A scientific advancement revolutionizing hereditary cancer testing
A revolutionary advancement in breast cancer risk assessment, the Myriad MyRisk Hereditary Cancer Test combines genetic information with family history and other clinical factors to determine your patient’s risk of developing a future cancer.
Expedited testing for time sensitive procedures
groundbreaking breast cancer risk-prediction tool
Due to insurance coverage and financial assistance 75% of patients pay $0
myRisk for your AFFECTED PATIENTS
Would Your Patient’s Risk of Developing Another Primary Cancer Affect Your Surgical Recommendation?
“When a patient is diagnosed with breast cancer, genetic testing can’t be an afterthought.” – Dr. Beth Dupree
myRisk for your UNAFFECTED PATIENTS
Would You Want Information to Help Your Patients Reduce Their Risk of Developing Breast Cancer?
“As a breast surgeon, it’s very important to me to know whether a patient carries a gene mutation that increases their risk for breast cancer.” – Dr. Paul Baron
Blending both genetic test status AND personal cancer family history, Myriad MyRisk represents the next generation of hereditary cancer risk testing by:
- Analyzing clinically significant genes
- Identifying elevated risk for 8 important cancers, including breast cancer
- Providing definitive results for up to 63 percent of variants of unknown significance (VUS) classifications from competing labs 2
Faster results for patients with breast cancer who have a surgery pending
- 11 breast cancer genes reported in 5-12 calendar days.
- Full Myriad MyRisk report in 14 calendar days or less.
Myriad is the unquestioned industry leader in variant classification and reclassification, employing various methods for variant interpretation in hereditary cancer testing to ensure analytical and interpretive accuracy are ever present, driving the best possible treatment and outcomes.
Myriad’s commitment to deliver accurate variant classifications to patients and their families lasts a lifetime:
- 2,868 variants reclassified between 2006 and 20163
- 60,064 amended reports between 2006 and 20163
RiskScore, Myriad’s groundbreaking breast cancer risk prediction tool, provides further clarity of a patient’s risk of developing breast cancer for those who do not have a deleterious mutation.
For eligible patients, you can reduce uncertainty even further. Using clinical risk factors and genetic-markers that have been clinically validated, RiskScore provides a woman’s 5-year and remaining lifetime risk for developing breast cancer.
RiskScore provides women with 5-year and remaining lifetime risk for developing breast cancer by combining her own clinical risk factors, family history, and unique genetic, ancestry-informed breast cancer risk markers. Validation of the PRS for all ancestries was presented at ASCO 2021, and development of the combined score is described in Hughes, et al. published in JCO 2021.
Myriad is committed to equity in care and advancing the science of RiskScore for all women. RiskScore is now available for all eligible, unaffected women without an inherited breast cancer syndrome, regardless of ancestry.
Myriad recognizes the importance of genetic testing. That’s why myRisk is accessible & affordable for patient
Testing through Myriad is affordable for your patients due to excellent insurance coverage and financial assistance:
- 75% of patients pay $0
- ≥90% of patients have or will qualify for a payment of $100 or less
Myriad will process and release samples that meet current NCCN and ASBrS (American Society of Breast Surgeons) recommendations for testing*
The value of using a multi-gene breast cancer panel testing to establish treatment options for diagnosed patients, as well as risk-reduction for family members, can have a profound impact on patient management choices and generational cancer incidence.
That’s why Myriad believes that patients should have testing options within their financial reach. Myriad has a financial assistance program for patients who meet certain financial and medical criteria.
* Some exceptions apply (e.g., government payers)
Myriad MyRisk Simple Practice Integration
It’s important that your office runs efficiently, so we’ve made it easy to incorporate Myriad MyRisk testing in your practice.
Online tools and tutorials are available to guide you and your staff through the process, and Myriad customer service representatives are always just a call away when you need immediate support – (800) 469-7423
Integrating myRisk into your practice is a matter of a few easy steps.
Starter kits and replacement tests can be ordered online 24 hours a day or over the phone with our Customer Service Team.
Once you send a test to our lab, a replacement kit will be sent to your office automatically, so you’ll always have them on hand.
When you register for a MyriadPro account you can access myRisk STAT results, our priority testing option that expedites turnaround time for patients with breast cancer who have a surgery pending.
Myriad has an easy screening process called myGeneHistory that patients can fill out at home or in your office.
Implementing myGeneHistory into your practice will help you identify which of your patients meet criteria for myRisk testing and can be easily filled out in your practice.
Learn about myGeneHistory’s benefits, usage, and how this new tool is a healthcare game-changer!
For information on how to implement myGeneHistory into your practice, fill out the form below.
Discussing genetic testing with your patients is a critical part of the process. It is important that the patient understands why the test is being ordered, how it will be performed, what types of results may be received, and how the results may impact their medical management. Myriad can provide tools and materials to help support patient education and informed consent for hereditary cancer testing. Additionally, Myriad has genetic counselors on staff to answer any questions that you may have as a provider, ensuring you are fully supported to discuss the myRisk test results with your patients.
In providing education and counseling to your patients, Myriad’s Patient Education Tools can guide your discussions on hereditary cancer syndromes. Some patients may find sample family letters helpful for disclosing information to their family members. You can download our sample family letter for the Myriad MyRisk test HERE.
myRisk testing can be submitted using either saliva or blood samples, which can be collected in only 2 to 5 minutes.
After sample collection, complete an easy-to use requisition. This process is streamlined if you’re already using Myriad’s MyGeneHistory, which automatically pre-populates the TRF form in your MyriadPro account.
When testing affected patients in cases where turnaround time is critical, you can request myRisk STAT and receive results for the genes related to breast cancer in as quickly as 5 to 12 days. A full myRisk report is then made available once the complete test is resulted.
To order myRisk STAT for a patient with breast cancer:
- Order myRisk and write in “STAT” on the Test Request Form
- Draw the sample and place everything in the FedEx package. Place the STAT sticker on FedEx package
- Preliminary results will only be available on your MyriadPro account
myRisk test results are usually available within 2 weeks, so it’s easy for your staff to schedule patient follow-up appointments
Test results will be mailed to your office and can also be accessed on your MyriadPro account.
Understanding myRisk Reports and Discussing Results with Patients
A comprehensive report will be provided for every patient who undergoes a myRisk test—whether their results are positive, negative, or elevated.
If you requested myRisk STAT, you’ll receive a preliminary report in 5 to 12 days after your affected patient’s sample was submitted, followed by the full report.
myRisk test reports classify results in one of three categories: NEGATIVE, POSITIVE, or ELEVATED, and the most important information is summarized at the beginning of the report.
Every full myRisk report begins with a summary of the test results, including the genetic test result, breast cancer RiskScore*, and a clinical history analysis. You will see one or a combination of colored symbols representing those results.
Any specific mutations found will be listed, along with other information including Variants of Uncertain Significance (VUS), a summary of society guidelines to optimize your medical management decisions in the MyRisk Management Tool, and a complete list of the genes tested.
Guides to help you and your patients understand their results are included with each report and available below.
As part of the Myriad lifetime commitment to patients, we update patient reports when new, clinically significant data related to a particular variant emerges.
If one of your patient’s variants is reclassified, you’ll receive an updated report with the revised result and myRisk Management Tool.
As a surgeon, you want to provide your patients with the best screening and potential surgical recommendation possible based on their personal risk of developing cancer.
Integrating myRisk into your practice can assist you in providing the best care for your patients. Order your physician guide today.
- American Society of Breast Surgeons 2019 Consensus Guideline on Hereditary Genetic Testing for Patients With and Without Breast Cancer
- Gradishar W, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. The Oncologist (2017).
- Mersch J, et al, Prevalence of variant classification following hereditary cancer genetic testing; JAMA, 2018
- Baron P, et al. A polygenic risk score can refine breast cancer risk in unaffected women referred for hereditary cancer testing. Presented at the American Society of Breast Surgeons Annual Meeting 2018.